Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C

BACKGROUND: Combination therapy with pegylated interferon, ribavirin and a first-generation NS3/4A protease inhibitor, telaprevir or boceprevir, is the new strategy for treatment of genotype 1 chronic hepatitis C virus infection. This combination improves therapeutic efficacy but it also increases t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Dermatol Case Rep
Main Authors: Kłujszo, Elżbieta, Parcheta, Piotr, Zarębska-Michaluk, Dorota, Ochwanowska, Ewa, Witkowska, Anna, Rakowska, Adriana, Rudnicka, Lidia, Kryczka, Wiesław
Formato: Artigo
Idioma:Inglês
Publicado em: Specjalisci Dermatolodzy 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4299703/
https://ncbi.nlm.nih.gov/pubmed/25621089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2014.1183
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados